Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer

功能化 MMP 抑制剂作为转移性癌症的放射诊断、放射治疗和放射增敏剂

• 批准号: DP0665794
• 负责人: Em/Prof Trevor Hambley
• 金额: $ 23.75万
• 依托单位: The University of Sydney
• 依托单位国家: 澳大利亚
• 项目类别: Discovery Projects
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-05-11 至 2009-05-10
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/DP0665794
• 关键词: Functionalised; MMP; Inhibitors; Radiodiagnostic; Radiotherapeutic

Identifying and treating malignant cancers is one of the major challenges facing the scientific and medical communities. In order to minimise side effects that accompany most treatments of cancer it is necessary to find ways of targeting the therapy to tumours and away from healthy organs. A difference between tumours and healthy tissues is the amount of the proteins (called MMPs) that tumours use to break out of their surroundings, to break into and out of the blood system, and to establish new colonies of cancer cells or metastases. This difference also distinguishes the most aggressive cancers. The purpose of this project is to develop means of identifying and targeting cancers using molecules that bind to these MMP proteins.

识别和治疗恶性癌症是科学和医学界面临的主要挑战之一。为了最大限度地减少大多数癌症治疗所伴随的副作用，有必要找到将治疗靶向肿瘤而远离健康器官的方法。肿瘤和健康组织之间的差异是肿瘤用来突破周围环境，进入和离开血液系统以及建立新的癌细胞集落或转移的蛋白质（称为MMPs）的数量。这种差异也区分了最具侵袭性的癌症。该项目的目的是开发使用与这些MMP蛋白结合的分子识别和靶向癌症的方法。